4DMT to Participate in 8th Annual Evercore Healthcare Conference

Core Insights - 4D Molecular Therapeutics is a late-stage biotechnology company focused on developing durable and disease-targeted therapeutics that aim to transform treatment paradigms and provide significant benefits to patients [3] Company Overview - The lead product candidate, 4D-150, is designed for the treatment of blinding retinal vascular diseases, specifically targeting wet age-related macular degeneration and diabetic macular edema, currently in Phase 3 development [3] - 4D-150 offers multi-year sustained delivery of anti-VEGF through a single intravitreal injection, significantly reducing the treatment burden compared to current bolus injections [3] - The second product candidate, 4D-710, is the first genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients via aerosol delivery [3] Upcoming Events - Management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 2:35 p.m. ET [2] - One-on-one meetings with management will also be available during the conference [1]